Current through Reg. 49, No. 38; September 20, 2024
(a) A facility shall meet the requirements of
this section. A facility may follow more stringent requirements than the
minimum standards required by this section.
(1) The facility owner and medical director
shall each demonstrate responsibility for the water treatment and dialysate
supply systems to protect hemodialysis patients from adverse effects arising
from known chemical and microbial contaminates that may be found in water and
improperly prepared dialysate, to ensure that the dialysate is correctly
formulated and meets the requirements of all applicable quality
standards.
(2) The facility owner
and medical director shall each assure that policies and procedures related to
water treatment, dialysate, and reuse are understandable and accessible to the
operator(s), and that the training program includes quality testing, risks and
hazards of improperly prepared concentrate, and bacterial issues.
(3) The facility owner and medical director
shall be informed prior to any alteration of, or any device being added to, the
water system.
(b) These
requirements apply to water intended for use in the delivery of hemodialysis,
including the preparation of concentrates from powder at a dialysis facility
and dialysate, and for reprocessing dialyzers for multiple use.
(1) The design for the water treatment system
in a facility shall be based on considerations of the source water for the
facility and designed by a water quality professional with education, training,
or experience in dialysis system design.
(2) When a public water system supply is not
used by a facility, the source water shall be tested by the facility at monthly
intervals in the same manner as a public water system as described in 30 Texas
Administrative Code, §290.104(relating to Summary of Maximum Contaminant
Levels, Maximum Residual Disinfectant Levels, Treatment Techniques, and Action
Levels), and §290.109 (relating to Microbial Contaminants) as adopted by
the Texas Commission on Environmental Quality.
(3) The physical space in which the water
treatment system is located shall be adequate to allow for maintenance,
testing, and repair of equipment. If mixing of concentrates is performed in the
same area, the physical space shall also be adequate to house and allow for the
maintenance, testing, and repair of the mixing equipment and for performing the
mixing procedure. Water distribution systems shall be configured as a
continuous recirculation loop, and to minimize biofilm formation, there shall
always be flow in a piping system, except during the backwash cycle of the
carbon tanks for direct feed systems.
(A) For
indirect feed systems a minimum of three feet per second water flow shall be
achieved in the distribution loop.
(B) For direct feed systems a minimum of 1.5
feet per second water flow shall be achieved in the distribution
loop.
(C) This rule shall not apply
to facilities providing only home training and support services utilizing
single patient devices.
(D) The
water treatment and distribution system shall include appropriate pressure
gauges, flow meters, sample ports, and other ancillary equipment necessary to
allow monitoring of the performance of individual system components and the
system as a whole, as determined by the facility medical director.
(4) The water treatment system
components shall be arranged and maintained so that bacterial and chemical
contaminant levels in the product water do not exceed the standards for
hemodialysis water quality described in §4.1.1 (concerning Maximum level
of chemical contaminants in water) and §4.1.2 (concerning Bacteriology of
water) of the American National Standards Institute (ANSI), Water Treatment
Equipment for Hemodialysis Applications, RD52:2004 Edition, published by
Association for the Advancement of Medical Instrumentation (AAMI). All
documents published by the AAMI as referenced in this section may be obtained
by writing the following address: 1110 North Glebe Road, Suite 220, Arlington,
Virginia 22201.
(A) Direct feed systems shall
include a means of verifiably preventing retrograde flow of water into the
distribution loop from the feed side of the reverse osmosis unit.
(B) Dead-end piping (risers with no flow,
branches with no fixture) shall not be installed. In any renovation work,
dead-end piping shall be removed.
(5) Written policies and procedures for the
operation of the water treatment system shall be developed, approved by the
medical director, implemented, and enforced. Parameters for the operation of
each component of the water treatment system shall be developed in writing and
known to the operator. Each major water system component shall be labeled in a
manner that identifies the device; describes its function, how performance is
verified, and actions to take in the event performance is not within an
acceptable range. Facility's policy and/or procedure for the bypass valves for
the carbon tanks and any other bypass valves considered to be critical by the
medical director shall have a means to minimize the likelihood the device will
be inadvertently bypassed during normal operation of the system.
(6) The materials of any components of water
treatment systems (including piping, storage, filters, and distribution
systems) that contact the product water shall not interact chemically or
physically so as to affect the purity or quality of the product water
adversely. Such components shall be fabricated from unreactive materials (e.g.,
plastics) or appropriate stainless steel. The use of materials that are known
to cause toxicity in hemodialysis, such as copper, brass, galvanized material,
or aluminum, is prohibited at any point beyond the water treatment component
used to remove contaminating metal ions (e.g., reverse osmosis system or
deionizer).
(7) Chemicals infused
into the water such as iodine, acid, flocculants, and complexing agents shall
be shown to be nondialyzable or shall be adequately removed from product water.
Systems shall be monitored in accordance with the manufacturer's direction for
use, and specific test procedures to verify removal of additives shall be
provided and documented. Chemical injection systems shall include a means of
regulating the metering pump to control the addition of chemical. This control
system shall be designed to tightly control addition of the chemical. The
control system shall ensure that chemical is added only when the water is
flowing through the pre-treatment cascade and that it is added in fixed
proportion to the water flow. If an automated control system is used to inject
the chemical, there shall be an independent monitor of the controlling
parameter.
(8) Each water treatment
system shall include reverse osmosis membranes or deionization tanks and a
minimum of two carbon tanks in series. If the source water is from a private
supply which does not use chlorine/chloramine, the water treatment system shall
include reverse osmosis membranes or deionization tanks and a minimum of one
carbon tank.
(A) Reverse osmosis systems, if
used, shall meet the standards in §6.2.7 (concerning Reverse Osmosis) of
the American National Standards Institute, Dialysate for Hemodialysis RD
52:2004 Edition, published by the AAMI.
(B) Deionization systems.
(i) Deionization systems, if used, shall be
monitored continuously to produce water of one megohm-centimeter (cm) or
greater specific resistivity (or conductivity of one microsiemen/cm or less) at
25 degrees Celsius. An audible and visual alarm shall be activated in the
facility to include the patient care area when the product water resistivity
falls below this level and the product water stream shall be prevented from
reaching any point of use.
(ii)
Patients shall not be dialyzed on deionized water with a resistivity less than
1.0 megohm-cm measured at the output of the final deionizer.
(iii) Deionization tanks if used shall be a
minimum of two mixed beds in series, and shall be used with resistivity
monitors including audible and visual alarms placed pre and post the final
deionization tank in the system and audible in the patient care area.
(iv) Feed water for deionization systems
shall be pretreated with activated carbon adsorption, or a comparable
alternative, to prevent nitrosamine formation.
(v) If a deionization system is the last
process in a water treatment system, it shall be followed by an ultrafilter or
other bacteria and endotoxin reducing device.
(vi) Facilities shall ensure that all devices
that are regenerated or reconstituted off site, such as deionizers, shall be
disinfected at the time of regeneration or reconstitution, so that contaminated
water is not reintroduced into the system after regeneration or
reconstitution.
(C)
Carbon tanks.
(i) The carbon tanks shall
contain granular activated carbon, with a minimum iodine number of 900.
Regenerated carbon shall not be used.
(ii) A minimum of two carbon adsorption beds
shall be installed in series with a sample port following the first bed. A
sample port shall also be installed following the second bed for use in the
event of free chlorine or cloramine breaking through the first bed.
(iii) The total empty bed contact time (EBCT)
shall be at least ten minutes, with the final tank providing at least five
minutes EBCT at the maximum flow rate through the bed. Carbon adsorption
systems used to prepare water for home dialysis or for portable dialysis
systems are exempt from the requirement for the second carbon and a ten minute
EBCT, if removal of chloramines to below 0.1 milligram (mg)/liter is verified
before each treatment.
(iv) A
sample port shall also be installed following the second bed for use in the
event of free chlorine or chloramine breaking through the first bed. Water from
this port(s) shall be tested for chlorine/chloramine levels at the beginning of
each treatment day prior to patients initiating treatment, prior to
reprocessing of dialyzers, and again prior to the beginning of each patient
shift. If there are no set patient shifts, testing should be performed every
four hours during hours of operation.
(v) Carbon beds are sometimes arranged as
series-connected pairs of beds so that they need not be overly large. The beds
within each pair are of equal size and water flows through them are parallel.
In this situation, each pair of beds should have a minimum empty bed contact
time of 5 minutes at the maximum flow rate through the bed. When series
connected pairs of beds are used, the piping should be designed to minimize
differences in the resistance to flow from inlet and outlet between each
parallel series of beds to ensure that an equal volume of water flows through
all beds.
(vi) All samples for
chlorine/chloramine testing shall be drawn when the water treatment system has
been operating for at least 15 minutes.
(vii) Tests for total chlorine, which include
both free and combined forms of chlorine, may be used as a single analysis with
the maximum allowable concentration of 0.1 mg/liter (L). Test results of
greater than 0.5 parts per million (ppm) for chlorine or 0.1 ppm for chloramine
from the port between the initial tank(s) and final tank(s) shall require
testing to be performed at the final exit and replacement of the initial
tank(s). Testing equipment, supplies and procedures shall be used in accordance
with the manufacturer's directions for use.
(viii) In a system without a holding tank, if
test results at the exit of the final tank(s) are greater than the parameters
for chlorine or chloramine described in this subparagraph, dialysis treatment
shall be immediately terminated to protect patients from exposure to
chlorine/chloramines, and the medical director shall be notified. In systems
with holding tanks, if the holding tank tests less than 0.1 mg/L for total
chlorine, the reverse osmosis (RO) may be turned off and the product water in
the holding tank may be used to finish treatments in process. The medical
director shall be notified.
(ix) If
means other than granulated carbon are used to remove chlorine/chloramine, the
facility's governing body shall approve such use in writing after review of the
safety of the intended method for use in hemodialysis applications. If such
methods include the use of additives, there shall be evidence the product water
does not contain unsafe levels of these additives.
(9) Water softeners, if used,
shall be tested at the end of the treatment day to verify their capacity to
treat a sufficient volume of water to supply the facility for the entire
treatment day, and shall be fitted with a mechanism to prevent water containing
the high concentrations of sodium chloride used during regeneration from
entering the product water line during regeneration.
(10) If used, the face(s) of timer(s) used to
control any component of the water treatment or dialysate delivery system shall
be visible to the operator at all times. Written evidence that timers are
checked for operation and accuracy each day of operation shall be
maintained.
(11) Filter housings,
if used during disinfectant procedures, shall include a means to clear the
lower portion of the housing of the disinfecting agents. Filter housings shall
be opaque.
(12) Ultrafilters, or
other bacterial reducing filters, if used, shall be fitted with pressure gauges
on the inlet and outlet water lines to monitor the pressure drop across the
membrane. Ultrafilters shall be included in routine disinfection
procedures.
(13) If used, storage
tanks shall have a conical or bowl-shaped base, and shall drain from the lowest
point of the base. Storage tanks shall have a tight-fitting lid, and be vented
through a hydrophobic 0.2 micron air filter. A means shall be provided to
effectively disinfect any storage tank installed in a water distribution
system.
(14) Ultraviolet (UV)
lights, if used, shall be monitored at the frequency in accordance with the
manufacturer's direction for use, and shall have an endotoxin reducing filter
located down stream of the device. A log sheet shall be used to record
monitoring.
(15) Water treatment
system piping shall be labeled to indicate the contents of the pipe and
direction of flow.
(16) The water
treatment system shall be continuously monitored during patient treatment and
be guarded by audible and visual alarms which can be seen and heard in the
dialysis treatment area should water quality drop below specific parameters.
Quality monitor sensing cells shall be located at the last component of the
water treatment system and at the beginning of the distribution system. No
water treatment components that could affect the quality of the product water
as measured by this device shall be located after the sensing cell.
(17) When deionization tanks do not follow a
reverse osmosis system, parameters for the rejection rate of the membranes
shall assure that the lowest rate accepted would provide product water in
compliance with §4.1.1 (concerning Maximum level of chemical contaminants
of water) of the American National Standards Institute, Dialysate for
Hemodialysis, RD 52:2004 Edition published by the AAMI.
(18) A facility shall maintain written logs
of the operation of the water treatment system for each treatment day. The log
book shall include each component's operating parameter and the action taken
when a component is not within the facility's set parameters.
(19) Microbiological testing of product water
shall be conducted.
(A) Routine
microbiological testing shall be conducted monthly. For a newly installed water
distribution system, or when any repairs, modifications or changes to the
configuration has been made to an existing system, weekly testing shall be
conducted for one month to verify that bacteria and endotoxin levels are
consistently within the allowed limits. Changes to components that are designed
to be replaced on a routine schedule such as filters, ultrafilters and
ultraviolet lamps do not require a period of more frequent testing.
(B) At a minimum, sample sites chosen for the
testing shall include the beginning of the distribution piping, the product
water in the reuse room, at any site of concentrate mixing, and the end of the
distribution piping.
(C) Samples
shall be collected prior to sanitization/disinfection of the water treatment
system, and the dialysis machines. Water testing results shall be routinely
trended and reviewed by the medical director in order to determine if results
seem questionable or if there is an opportunity for improvement. The medical
director shall determine if there is a need for retesting. If internal testing
is performed with repeated results of "no growth" for three consecutive months,
the testing shall be validated via an outside laboratory. A calibrated loop may
not be used in microbiological testing of water samples. Colonies shall be
counted using a magnifying device.
(D) Product water used to prepare dialysate,
concentrates from powder, or to reprocess dialyzers for multiple use shall
contain a total viable microbial count less than 200 colony forming units
(CFU)/millimeter (ml) and an endotoxin concentration less than 2 endotoxin
units (EU)/ml. The action level for the total viable microbial count in the
product water shall be 50 CFU/ml and the action level for the endotoxin
concentration shall be 1 EU/ml.
(E)
If the action levels described at subparagraph (D) of this paragraph are
observed in the product water, the medical director shall be notified and
corrective measures shall be taken promptly to reduce the levels into an
acceptable range.
(F) All bacteria
and endotoxin results shall be recorded on a log sheet in order to identify
trends that may indicate the need for corrective action.
(20) If ozone generators are used to
disinfect any portion of the water or dialysate delivery system, the ozone
generator shall be capable of delivering ozone at the concentration and for the
exposure time specified and in accordance with the manufacturer's direction for
use. Testing based on the manufacturer's direction shall be used to measure the
ozone concentration each time disinfection is performed, to include testing for
safe levels of residual ozone at the end of the disinfection cycle. Testing for
ozone in the ambient air shall be conducted on a periodic basis as recommended
by the manufacturer. The records of all testing shall be maintained in a log.
The frequency of disinfection shall be performed at least monthly.
(21) If used, hot water disinfection systems
shall utilize AAMI quality water, be capable of delivering hot water at the
temperature and for the exposure time specified and in accordance with the
manufacturer's direction for use; and be monitored for temperature and time of
exposure to hot water as specified by the manufacturer. Temperature of the
water shall be monitored at a point furthest from the water heater, where the
lowest water temperature is likely to occur. The water temperature shall be
measured each time a disinfection cycle is performed. A record that verifies
successful completion of the heat disinfection shall be maintained. The
frequency of disinfection shall be performed at least monthly.
(22) After chemical disinfection, a mechanism
shall be incorporated to ensure that the equipment and the system are restored
to a safe condition prior to using the equipment and the product water being
used for dialysis applications. The results of all absence testing shall be
documented. The frequency of disinfection shall be performed at least monthly.
A mechanism shall be incorporated in the distribution system to ensure that
disinfectant does not drain from pipes during the disinfection
period.
(23) Users shall establish
a procedure for regular disinfection of the line between the outlet from the
water distribution system and the back of the dialysis machine.
(24) Samples of product water used for
dialysis shall be submitted for chemical analysis every six months, and after a
change of the reverse osmosis membranes, and shall demonstrate that the quality
of the product water used to prepare dialysate, concentrates from powder, or to
reprocess dialyzers for multiple use meets §4.1.1 (concerning Maximum
level of chemical contaminants in water) of the American National Standards
Institute, Water Treatment Equipment for Hemodialysis Applications, RD52:2004
Edition, published by the AAMI.
(A) Samples
for chemical analysis shall be collected at the most distal point in each water
distribution loop. All other outlets from the distribution loops shall be
inspected to ensure that the outlets are fabricated from compatible materials.
Appropriate containers and pH adjustments shall be used to ensure accurate
determinations. New facilities or facilities that add or change the
configuration of the water distribution system shall draw samples at the most
distal point for each water distribution loop, and then every six months
thereafter.
(B) Additional chemical
analysis shall be submitted when any modification or change to the
configuration of the existing system are made to the water treatment system, or
if the percent rejection of a reverse osmosis system decreased 5.0% or more
from the percent rejection measured at the time the water sample for the
preceding chemical analysis was taken.
(25) Facility records shall include all test
results and evidence that the medical director has reviewed the results of the
water quality testing and directed corrective action when indicated.
(26) Only persons qualified by the education
or experience described in §
117.46(f)
of this title (relating to Qualifications of Staff) may operate, repair, or
replace components of the water treatment system.
(c) Dialysate.
(1) The facility shall develop, implement,
maintain, and evaluate quality assessment and performance improvement (QAPI)
procedures to ensure ongoing conformance to policies and procedures regarding
dialysate quality.
(2) Each
facility shall set all hemodialysis machines to use only one family of
concentrates. When new machines are put into service or the concentrate family
or concentrate manufacturer is changed, dialysate samples shall be taken from
each machine, and shall be sent to a laboratory for verification of the
dialysate electrolyte values.
(3)
Prior to each patient treatment, staff shall verify the dialysate conductivity
and pH of each machine with an independent device.
(4) Bacteriological testing shall be
conducted.
(A) For newly installed bicarbonate
concentrate mixing and delivery systems, weekly testing shall be conducted for
one month to verify that bacteria and endotoxin levels are consistently within
the allowed limits. Responsible facility staff shall develop a schedule to
ensure each hemodialysis machine is tested quarterly for bacterial growth and
the presence of endotoxins. Hemodialysis machines of home patients,
conventional and integrated dialysis systems, shall be cultured monthly until
results not exceeding 200 colony forming units per milliliter are obtained for
three consecutive months, and thereafter quarterly samples shall be cultured.
This subparagraph does not apply to closed systems as defined in §
117.2(11)
of this title (relating to Definitions).
(B) Dialysate shall contain less than 200
CFU/ml and an endotoxin concentration of less than 2 EU/ml. The action level
for total viable microbial count shall be 50 CFU/ml, and the action level for
endotoxin concentration shall be 1 EU/ml.
(C) Disinfection and retesting shall be done
when bacterial or endotoxin counts exceed the action levels. The medical
director shall be notified. Additional samples shall be collected when there is
a clinical indication of a pyrogenic reaction and/or septicemia.
(5) Only a qualified licensed
nurse may use an additive to increase concentrations of specific electrolytes
in the acid concentrate. Mixing procedures shall be followed as specified by
the additive manufacturer. When additives are prescribed for a specific
patient, the container holding the prescribed acid concentrate shall be labeled
with the name of the patient, the final concentration of the added electrolyte,
the date the prescribed concentrate was made, and the name of the person who
mixed the additive.
(6) All
components used in concentrate preparation systems (including mixing and
storage tanks, pumps, valves, and piping) shall be fabricated from materials
(e.g., plastics or appropriate stainless steel) that do not interact chemically
or physically with the concentrate so as to affect its purity, or with the
germicides used to disinfect the equipment. The use of materials that are known
to cause toxicity in hemodialysis such as copper, brass, galvanized material,
and aluminum is prohibited.
(7)
Facility policies shall address means to protect stored dialysate components
(acid concentrates, bicarbonate concentrates, or bulk storage of dialysate
components) from tampering or from degeneration due to exposure to extreme heat
or cold.
(8) Procedures shall be
developed, implemented, and enforced:
(A) to
control the transfer of acid concentrates from the delivery container to the
storage tank and prevent the inadvertent mixing of different concentrate
formulations. The storage tanks shall be clearly labeled;
(B) the tank and associated plumbing shall
form an integral system to prevent contamination of the acid concentrate;
and
(C) the storage tank and inlet
and outlet connections, if remote from the tank, shall be secured and clearly
labeled.
(9) Concentrate
mixing systems shall include a purified water source, a suitable drain, and a
ground fault protected electrical outlet.
(A)
Operators of mixing systems shall use personal protective equipment as
specified and in accordance with the manufacturer's direction for use during
all mixing processes.
(B) The
manufacturer's directions for use of a concentrate mixing system shall be
followed, including instructions for mixing the powder with the correct amount
of water. The number of bags or weight of powder added shall be determined and
recorded.
(C) The mixing tank shall
be clearly labeled to indicate the fill and final volumes required to correctly
dilute the powder.
(D) Systems for
preparing either bicarbonate or acid concentrate from powder shall be monitored
according to the manufacturer's directions for use, to ensure compliance with
paragraph (11)(A) of this subsection.
(E) Concentrates shall not be used or
transferred to holding tanks or distribution systems until all tests are
completed per manufacturer's specifications and in accordance with the
manufacturer's directions for use. The results of the tests shall be
documented, with the signature of the person who completed the tests.
(F) If a facility designs its own system for
mixing concentrates, procedures shall be developed and validated using an
independent laboratory to ensure proper mixing of the concentrate, including
establishment of acceptable limits for tests of proper concentration.
(10) Acid concentrate mixing tanks
shall be designed to allow the inside of the tank to be rinsed when changing
concentrate formulas.
(A) Acid mixing systems
shall be designed and maintained to prevent rust and corrosion.
(B) Acid concentrate mixing tanks shall be
emptied completely and rinsed with product water before mixing another batch of
concentrate to prevent cross contamination between different batches.
(C) Acid concentrate mixing equipment shall
be disinfected as specified by the equipment manufacturer or, in the case where
no specifications are given, as defined by facility policy.
(D) Records of disinfection and rinsing of
disinfectants to safe residual levels shall be maintained.
(11) Bicarbonate concentrate mixing tanks
shall have conical or bowl-shaped bottoms and shall drain from the lowest point
of the base. The tank design shall allow all internal surfaces to be
disinfected and rinsed.
(A) Bicarbonate
concentrate mixing tanks shall not be pre-filled the night before use, and
mixed solution shall not remain in mixing or holding tanks overnight.
(B) If disinfectant remains in the mixing
tank overnight, this solution shall be completely drained, the tank rinsed and
tested for residual disinfectant prior to preparing the first batch of that day
of bicarbonate concentrate.
(C) The
container shall be emptied and rinsed with product water prior to mixing a new
batch of bicarbonate solution, and unused portions of bicarbonate concentrate
shall not be mixed with fresh concentrate.
(D) At a minimum, bicarbonate distribution
systems shall be disinfected weekly. More frequent disinfection shall be done
if required in accordance with the manufacturer's direction for use, or if
dialysate culture results are above the action level.
(E) If jugs are reused to deliver bicarbonate
concentrate to individual hemodialysis machines:
(i) jugs shall be emptied of concentrate,
rinsed, and inverted to drain at the end of each treatment day;
(ii) pick-up tubes shall be rinsed and
allowed to air dry at the end of each treatment day;
(iii) at a minimum, jugs and pick-up tubes
shall be disinfected weekly, more frequent disinfection shall be considered by
the facility QAPI committee if dialysate culture results are above the action
level; and
(iv) following
disinfection, jugs shall be drained, rinsed free of residual disinfectant, and
inverted to dry. Pick-up tubes shall be rinsed free of residual disinfectant
and allowed to air day. Testing for residual disinfectant shall be done and
documented.
(12) All mixing tanks, bulk storage tanks,
dispensing tanks, and containers for single hemodialysis treatments shall be
labeled as to the contents.
(A) Prior to
batch preparation, a label shall be affixed to the mixing tank that includes
the date of preparation and the chemical composition or formulation of the
concentrate being prepared. This labeling shall remain on the mixing tank until
the tank has been emptied.
(B) Bulk
storage/dispensing tanks shall be permanently labeled to identify the chemical
composition or formulation of their contents.
(C) At a minimum, single-machine containers
shall be labeled with sufficient information to differentiate the contents from
other concentrate formulations used in the facility and permit positive
identification by users of container contents.
(13) Permanent records of batches produced
shall be maintained to include the concentrate formula produced, the volume of
the batch, lot number(s) of powdered concentrate packages, the manufacturer of
the powdered concentrate, date and time of mixing, test results, person
performing mixing, and expiration date (if applicable).
(14) If acid and bicarbonate concentrates are
prepared in the facility, preventive maintenance shall be completed in
accordance with the manufacturer's direction for use. Records shall be
maintained indicating the date, time, person performing the procedure, and the
results (if applicable).
(d) Reuse of hemodialyzers and related
devices.
(1) Reuse practice in a facility
shall comply with the American National Standards Institute (ANSI), Reuse of
Hemodialyzers, Third Edition, ANSI/AAMI RD47:2002 and RD47:2002/A1:2003,
published by the AAMI.
(2) Dialyzer
manufacturer's labeling shall be reviewed to determine if a specific dialyzer
requires special considerations.
(3) A transducer protector shall be replaced
when wetted during a dialysis treatment, and shall be used for one treatment
only. Equipment with internal transducer protectors shall be inspected
quarterly to ensure that it has not been contaminated.
(4) Arterial lines may be reused only when
the arterial lines are labeled to allow for reuse by the manufacturer, and the
manufacturer-established protocols for the specific line have been approved by
the United States Food and Drug Administration.
(5) The water supply in the reuse room shall
incorporate a check valve to prevent chemical agents used from inadvertently
back flowing into the water distribution system.
(6) Ventilation systems in the reuse room
shall be connected to an exhaust system to the outside which is separate from
the building exhaust system, have an exhaust fan located at the discharge end
of the system, and have an exhaust duct system of noncombustible
corrosion-resistant material as needed to meet the planned usage of the system.
Exhaust outlets shall be above the roof level and arranged to minimize
recirculation of exhaust air into the building.
(7) A facility shall establish, implement,
and enforce a policy for dialyzer reuse criteria (including any facility-set
number of reuses allowed), which is included in patient education materials and
posted in the waiting room and patient treatment areas. A dialyzer may be
reused only if that dialyzer's original volume is measured and recorded prior
to its first use, and the volume of that dialyzer is used as the basis for
discard for that dialyzer.
(8) A
facility shall consider and address the health and safety of patients sensitive
to disinfectant solution residuals.
(9) A facility shall provide each patient
with information regarding the reuse practices at the facility and the
opportunity to have questions answered.
(10) A facility shall restrict the
reprocessing room to authorized personnel during the reprocessing of
dialyzers.
(11) A facility shall
obtain written informed consent of the patient or legal
representative.
(e) If a
facility participates in centralized reprocessing at a different location, in
which dialyzers from multiple facilities are reprocessed at one site, the
facility shall:
(1) ensure direct
communication with the medical director at the centralized reprocessing center
and the facility's medical director;
(2) require the use of automated reprocessing
facility;
(3) maintain
responsibility and accountability for the entire reuse process;
(4) adopt, implement, and enforce policies to
ensure that the transfer and transport of used and reprocessed dialyzers to and
from the off-site location does not increase contamination of the dialyzers,
staff, or the environment;
(5)
assure that each dialyzer is returned to the appropriate facility or patient
home, and, in the case of home patients who participate in a dialyzer
reprocessing program, a system shall be established to verify that the correct
dialyzers are being returned to each patient's home; and
(6) provide department staff access to the
off-site reprocessing site as part of a facility inspection.